Status:
COMPLETED
A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
Lead Sponsor:
ViiV Healthcare
Conditions:
CHRONIC HEPATITIS B
Eligibility:
All Genders
15+ years
Phase:
PHASE4
Brief Summary
The efficacy of lamivudine in Hepatitis Be Antigen (HBeAg) positive Asian patients of chronic hepatitis has been well established.The evidence in HBeAg negative patients is limited. Limited sustained ...
Eligibility Criteria
Inclusion
- Confirmed active liver disease due to Hepatitis B virus.
- Patients must have adequate blood \& liver functions.
- Female patients of child-bearing potential must be non pregnant and willing to abstain from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication or be willing to consistently and correctly use an acceptable method of birth control.
- Patients who have serious concurrent illnesses other than hepatitis B like cancer, severe heart disease, uncontrolled diabetes mellitus or AIDS will not be eligible.
Exclusion
- Persons allergic to lamivudine or suffering from hepatitis C, D or E infection or taking alcohol will not be eligible.
Key Trial Info
Start Date :
February 9 2002
Trial Type :
INTERVENTIONAL
End Date :
January 23 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00354653
Start Date
February 9 2002
End Date
January 23 2007
Last Update
March 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Clinical Trials Call Center
Tehran, Iran, 1919954186